Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Crescent Biopharma, Inc.NASDAQ: CBIO
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin at -2240.9%
Net margin was -2240.9% in Q1 FY2026. On a trailing-twelve-month basis it was -1363.9%. Over 3 fiscal years it widened by 60832.1 pp.
Context
- Net margin widened in 1 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 5 analysts of -861.2% for the fiscal year ending Dec 2026, up from -1419.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2240.9%-1388.8 pp QoQ
- Last fiscal yearDec 2025
- -1419.6%— YoY
- LTMMar 2026
- -1363.9%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +558.4 pp | — |
| 3 years | +60832.1 pp | +846.1 pp | -59986.0 pp |
| 5 years | +1393.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1419.6%
- Year-over-year change
- —
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1419.6% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | -368994.2% | -306742.5pp |
| FY2022 | 2022-12-31 | -62251.7% | -56782.8pp |
| FY2021 | 2021-12-31 | -5469.0% | — |
Net Margin vs competitors
How CBIO compares with its peers on the latest reported figures
- CBIO's LTM Mar 2026 net margin of -1363.9% is the 6th highest of the 7 companies compared; the peer median is -105.6%.
- Over three fiscal years its change of +60832.1 pp compares with a peer median of +62.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 48.0% | +99.2 pp | +497.8 pp | |
| LTM Sep 2026 | 16.3% | +63.4 pp | -106.7 pp | |
| LTM Mar 2026 | -44.8% | -8.2 pp | +29.9 pp | |
| LTM Mar 2026 | -166.4% | -194.6 pp | +164.0 pp | |
| LTM Jun 2026 | -386.3% | -269.5 pp | +95.5 pp | |
| LTM Mar 2026 | -1363.9% | — | +60832.1 pp | |
| LTM Sep 2026 | -275986.6% | -267350.8 pp | -12487.7 pp | |
VRXAVeraxa Biotech Holding AG | — | — | — | — |
| FY2025 | — | — | — | |
NBPNovaBridge Biosciences | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding CBIO) | -105.6% | -101.4 pp | +62.7 pp | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| Weighted Avg Shares | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
| Weighted Avg Shares (Diluted) | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.